🎯 Drug Targets

Browse 6 drug targets with druggability analysis, composite scores, and clinical context

6
Targets
0
High Druggability
0.55
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 0Low: 6Unknown: 0
Avg druggability score: 0.393
Clinical Pipeline
Approved: 1Phase III: 0Phase II: 2Phase I: 3Preclinical: 0
Total compounds: 9 · Approved: 0
Filtered by: class=epigenetic_regulator, druggability=Low — 6 results
SIRT6 Sirtuin-6 Phase I
Epigenetic Regulator Low Druggability
Score
0.59
Drug.
0.41
Safety
0.60
Drugs
1
Hyps
2
Papers
36
Small molecule activation or inhibition of NAD+-dependent deacetylase activity
TET2 Tet methylcytosine dioxygenase 2 Phase II
Epigenetic Regulator Low Druggability
Score
0.58
Drug.
0.42
Safety
0.60
Drugs
2
Hyps
6
Papers
65
Small molecule enhancers of TET2 enzymatic activity or cofactor supplementation
PRMT1 Protein arginine methyltransferase 1 Phase I
Epigenetic Regulator Low Druggability
Score
0.57
Drug.
0.36
Safety
0.50
Drugs
1
Hyps
1
Papers
32
Small molecule inhibitor of protein arginine methyltransferase activity
HDAC3 Histone Deacetylase 3 Approved
Epigenetic Regulator Low Druggability
Score
0.56
Drug.
0.41
Safety
0.40
Drugs
2
Hyps
5
Papers
36
Small molecule inhibitor of histone deacetylase enzymatic activity
KDM6A Lysine demethylase 6A Phase I
Epigenetic Regulator Low Druggability
Score
0.52
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
1
Papers
36
Small molecule inhibition of histone demethylase activity
BRD4 Bromodomain-containing protein 4 Phase II
Epigenetic Regulator Low Druggability
Score
0.45
Drug.
0.40
Safety
0.62
Drugs
2
Hyps
1
Papers
35
BRD4 inhibition reduces neuroinflammatory super-enhancer activity while biased BRD4 modulators can selectively restore neuroprotective gene expression